Genprex Completes Phase 1 Dose Escalation Portion of Acclaim-3 Clinical Trial Results from Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of REQORSA and Tecentriq in ES-SCLC Patients AUSTIN, Texas , Dec. 16, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 dose escalation portion of the Acclai ...

Core Viewpoint - Genprex, Inc. has entered into an exclusive license agreement with the University of Michigan for its lead drug candidate, Reqorsa® Gene Therapy, in combination with ALK-inhibitors for the treatment of ALK-positive lung cancer [1][2]. Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its ONCOPREX® Delivery System to administer disease-fighting genes [6]. - The company is currently evaluating Reqorsa® Gene Therapy in two clinical trials for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [6]. Product Details - Reqorsa® Gene Therapy (quaratusugene ozeplasmid) targets cancer cells by delivering the TUSC2 gene using non-viral nanoparticles, aiming to interrupt cancer cell signaling and promote apoptosis [4]. - The therapy has shown positive preclinical data, indicating its potential effectiveness in treating ALK-positive lung cancer, particularly in patients resistant to alectinib [2][3]. Research and Development - Research at the University of Michigan has demonstrated that Reqorsa can decrease cell growth and proliferation in ALK-positive NSCLC cell lines by activating apoptotic pathways [3]. - The company believes that Reqorsa may be an effective treatment for patients progressing on ALK inhibitors, supporting further clinical studies [3]. Intellectual Property Strategy - Genprex is enhancing its intellectual property portfolio for Reqorsa, which may benefit patients with various types of cancers, thereby widening its exclusivity for drug combinations [2].

UNITED STATES Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share GNPX The Nasdaq Capital Market SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __ ...

Core Insights - Genprex, Inc. announced positive preclinical data for its lead drug candidate, Reqorsa® Gene Therapy, which modulates immune responses against cancer [1][2] - The findings will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting, indicating the growing evidence of Reqorsa's anti-tumor mechanisms [2][4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its Oncoprex® Delivery System [7][8] - The company collaborates with academic institutions to advance its drug candidates and has received Fast Track Designation and Orphan Drug Designation from the FDA for its lung cancer programs [8] Research Findings - The study involved TUSC2 Knock Out (KO) and Wild Type (WT) mice, analyzing immune responses through flow cytometry [2][3] - In the Reqorsa supplemented group, tumor growth was significantly reduced, with a notable decrease in T regulatory cells and an increase in Cytotoxic T cells and NK cells [3][4] - The research suggests that Reqorsa can enhance immune responses against tumors, even in individuals with low TUSC levels due to various health conditions [4][5] Product Details - Reqorsa consists of a TUSC2 gene expressing plasmid encapsulated in lipid-based nanoparticles, specifically targeting cancer cells while minimizing normal tissue uptake [5][8] - Laboratory studies indicate that the uptake of TUSC2 in tumor cells post-Reqorsa treatment is 10 to 33 times higher than in normal cells [5] Future Developments - Following the conference, the poster detailing the research will be available for download on Genprex's website [6]

AUSTIN, Texas, Oct. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its participation in the upcoming BIO Europe Conference, taking place Nov. 4-6, 2024 in Stockholm, Sweden and taking place virtually Nov. 12-13, 2024.Attending in-person will be Genprex's Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, E ...

Preclinical Data Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics AUSTIN, Texas , Oct. 28, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that research collaborators delivered poster presentations at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held October 23-25 ...

Research to Study TUSC2 Combined with ALK-InhibitorsCollaboration with Non-Profit Patient-Focused Research Group Expands Potential Lung Cancer Patient Population for Reqorsa® Gene TherapyAUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company has entered into a Sponsored Research Agreement (SRA) with the Univer ...

Poster Presentation to Focus on Reqorsa's Ability to Modulate In Vivo Immune Responses Against Cancers AUSTIN, Texas, Oct. 7, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College were selected to present at the upcoming 39th Annual Society for Immunotherapy of Cancer Meeting being held ...

Company's CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs AUSTIN, Texas, Sept. 23, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in CEO/CFO Magazine discussing the Company's novel gene therapies for cancer and diabetes. I ...

Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma AUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program. The Board is comprised of four world-reno ...